Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative immunotherapy versus chemo-immunotherapy with early response stratification in resectable gastric and esophagogastric junction adenocarcinoma
2018-000383-28Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Jul 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, relatlimab, docetaxel, oxaliplatin, fluorouracil and 1 more in gastric cancer (GC) and Esophago-Gastric Adenocarcinoma (4 arms), sponsored by Universitätsmedizin Essen. Primary endpoint: Pathological complete response rate. Started Jul 2018; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on 2018-000383-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000383-28.